TransMedics Group, Inc. (NASDAQ:TMDX) Receives $134.00 Average Price Target from Brokerages

TransMedics Group, Inc. (NASDAQ:TMDX) has been given an average recommendation of “Hold” by the thirteen analysts that are presently covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $134.00.

A number of equities research analysts have recently weighed in on the company. Oppenheimer downgraded TransMedics Group from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 6th. TD Cowen lowered their price target on TransMedics Group from $190.00 to $120.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. JPMorgan Chase & Co. boosted their price target on TransMedics Group from $114.00 to $149.00 and gave the company a “neutral” rating in a report on Wednesday, February 25th. Needham & Company LLC lowered their price target on TransMedics Group from $174.00 to $142.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Finally, Canaccord Genuity Group lowered their price target on TransMedics Group from $152.00 to $124.00 and set a “buy” rating for the company in a report on Wednesday, May 6th.

Institutional Investors Weigh In On TransMedics Group

A number of institutional investors have recently made changes to their positions in the company. Harvest Fund Management Co. Ltd acquired a new position in TransMedics Group during the 3rd quarter valued at approximately $29,000. Optiver Holding B.V. increased its position in TransMedics Group by 248.1% in the third quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after buying an additional 191 shares during the period. North Star Investment Management Corp. acquired a new stake in TransMedics Group in the first quarter worth $30,000. Ascentis Independent Advisors acquired a new stake in TransMedics Group in the first quarter worth $30,000. Finally, Allworth Financial LP increased its position in TransMedics Group by 74.3% in the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after buying an additional 113 shares during the period. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Stock Performance

Shares of TransMedics Group stock opened at $71.37 on Tuesday. The firm has a market cap of $2.47 billion, a PE ratio of 16.22 and a beta of 1.91. The firm’s 50-day simple moving average is $89.49 and its 200-day simple moving average is $117.28. The company has a debt-to-equity ratio of 1.70, a quick ratio of 6.19 and a current ratio of 6.74. TransMedics Group has a 1 year low of $60.10 and a 1 year high of $156.00.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.32). The firm had revenue of $173.93 million during the quarter, compared to the consensus estimate of $174.44 million. TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The firm’s quarterly revenue was up 21.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.70 earnings per share. Equities analysts forecast that TransMedics Group will post 1.98 earnings per share for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.